NUCYNTA ER Drug Profile, 2023


Book Description

NUCYNTA ER Drug Profile, 2023

This report focuses on NUCYNTA ER and covers the following critical aspects of this drug:

  • United States patents
  • Expired United States patents
  • FDA Paragraph IV patent challenges
  • District Court patent litigation
  • Patent Trial and Appeal Board (PTAB) patent cases
  • European supplementary protection certificates (SPCs)
  • Clinical trials
  • Drug prices
  • Finished product suppliers
  • Raw active pharmaceutical ingredient (API) sources













Annual Report


Book Description




Information Sources


Book Description













Urban Land


Book Description